{"id":"57544fbf-bc4c-5a00-ad99-70bd2120b717","stable_key":"d71929ae-ed38-52ed-b512-f92b9b148b71:ss-apt2-stat3-coip","predicate":"has_contextual_experimental_result","statement":"Solasonine reduced APT2-STAT3 co-immunoprecipitation.","claim_class":"observational","status":"source_derived_draft","evidence_grade":"ungraded","direction":"negative","is_public":true,"mechanism_event_id":"47083c0e-9f46-54f6-a6ae-e5cc723d9054","mechanism_event_label":"ss-apt2-stat3-coip","subject":{"id":"6410ac1a-e95f-550f-955a-6725a3765ee3","slug":"solasonine","display_name":"Solasonine","entity_type_key":"small_molecule"},"object":{"id":"b8c50ea4-006f-53d9-89ac-f36985415f91","slug":"human-apt2-stat3-coimmunoprecipitation","display_name":"APT2-STAT3 co-immunoprecipitation in human cells","entity_type_key":"cellular_process"},"evidence_count":1,"mechanism_event":{"id":"47083c0e-9f46-54f6-a6ae-e5cc723d9054","stable_key":"d71929ae-ed38-52ed-b512-f92b9b148b71:ss-apt2-stat3-coip","event_type":"experimental_result","label":"ss-apt2-stat3-coip","description":"Solasonine reduced APT2-STAT3 co-immunoprecipitation.","status":"provisional","compartment":null,"participants":[{"entity":{"id":"6410ac1a-e95f-550f-955a-6725a3765ee3","slug":"solasonine","display_name":"Solasonine","entity_type_key":"small_molecule"},"role":"subject","stoichiometry":null,"state_label":"","sequence_order":0,"notes":""},{"entity":{"id":"b8c50ea4-006f-53d9-89ac-f36985415f91","slug":"human-apt2-stat3-coimmunoprecipitation","display_name":"APT2-STAT3 co-immunoprecipitation in human cells","entity_type_key":"cellular_process"},"role":"target","stoichiometry":null,"state_label":"","sequence_order":1,"notes":""},{"entity":{"id":"f2ffef5b-5457-50a8-b787-b8f24430f610","slug":"lypla2","display_name":"LYPLA2","entity_type_key":"protein"},"role":"complex member","stoichiometry":null,"state_label":"","sequence_order":2,"notes":""},{"entity":{"id":"dc129d3d-aaa0-5511-9a60-3e3880b0eb0f","slug":"stat3","display_name":"STAT3","entity_type_key":"protein"},"role":"complex member","stoichiometry":null,"state_label":"","sequence_order":3,"notes":""}]},"contexts":[{"dimension":"experimental_model","value_text":"Human NOZ and GBC-SD gallbladder cancer cells","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"exposure","value_text":"25 micromolar solasonine; main methods specify 48-hour cellular drug exposure.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"limitations","value_text":"Human cancer-cell experiments; no clinical or dietary inference. Solasonine exposure is not equivalent to APT2 depletion, ML349, or sulforaphane. Mutant rescue does not by itself establish selectivity or normal baseline mutant function. Figure 5C calls this APT2 activity, but Methods 2.17 describes an anti-LYPLA2 ELISA with mass-concentration standards and an HRP/TMB readout from cell supernatants. No direct APT2 substrate-turnover assay is described there. The result is retained as an author-labelled activity proxy, not established catalytic inhibition. This methodological qualification does not invalidate the separately reported binding or cellular observations.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"organism","value_text":"Human","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"primary_locator","value_text":"Figure 5D-E; Results 3.5.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"primary_references","value_text":"https://doi.org/10.1002/ptr.70245","comparator":null,"unit":null,"notes":"","entity":null}],"evidence":[{"id":"6b00e26d-2983-5db0-bf27-6e7a34ec3b7f","evidence_kind":"source_excerpt","locator":"Lines 114-120","start_line":114,"end_line":120,"excerpt":"Solasonine reduced APT2-STAT3 co-immunoprecipitation.\nprimary_references: https://doi.org/10.1002/ptr.70245\nprimary_locator: Figure 5D-E; Results 3.5.\norganism: Human\nexperimental_model: Human NOZ and GBC-SD gallbladder cancer cells\nexposure: 25 micromolar solasonine; main methods specify 48-hour cellular drug exposure.\nlimitations: Human cancer-cell experiments; no clinical or dietary inference. Solasonine exposure is not equivalent to APT2 depletion, ML349, or sulforaphane. Mutant rescue does not by itself establish selectivity or normal baseline mutant function. Figure 5C calls this APT2 activity, but Methods 2.17 describes an anti-LYPLA2 ELISA with mass-concentration standards and an HRP/TMB readout from cell supernatants. No direct APT2 substrate-turnover assay is described there. The result is retained as an author-labelled activity proxy, not established catalytic inhibition. This methodological qualification does not invalidate the separately reported binding or cellular observations.","model_system":"Human NOZ and GBC-SD gallbladder cancer cells","directness":"reported_statement","verification_status":"source_derived_draft","notes":"Curator paraphrase, not a publisher quotation. Methodological inference is explicitly identified.","relationship":"supports","weight":1.0,"link_notes":"","source":{"id":"15a55d0b-bd44-54e4-9080-5526d1a9744d","stable_key":"import-d71929ae-ed38-52ed-b512-f92b9b148b71","title":"APT2, STAT3 and GPX4: opposing branches and assay qualification","document_type":"imported_text","citation_label":"Primary observations: 10.1038/s41467-025-56344-5 and 10.1002/ptr.70245; selected full-text review 2026-09-20.","file_path":"","sha256":"6fd94803c436074e7b2c15e9a817e751c3d95f6fe1d35a4af63ab641a8f33fe0","revision_id":"d59d5472-18d2-5feb-bc2e-529ceda00956","review_status":"unverified_draft","notes":""}}],"relations":[],"conflicts":[],"corrections":[],"research":null}